Pharmaceutical stocks are making a comeback as valuations remain attractive and companies successfully address patent cliff concerns, according to UBS global head of biotech research Michael Yee. In ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

Biotech interviews in 2026 demand more than just lab expertise—they assess critical thinking, communication, and the ability to operate within regulatory and fast-paced environments. Employers seek ...

So, what will the early months of 2026 look like for the biotech sector? First, let me say that the biotech sector being 'en fuego' over the past three quarters has made my year as far as my portfolio ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...